全文获取类型
收费全文 | 3141篇 |
免费 | 345篇 |
国内免费 | 2篇 |
出版年
2022年 | 39篇 |
2021年 | 62篇 |
2020年 | 54篇 |
2019年 | 49篇 |
2018年 | 59篇 |
2017年 | 48篇 |
2016年 | 78篇 |
2015年 | 122篇 |
2014年 | 144篇 |
2013年 | 188篇 |
2012年 | 219篇 |
2011年 | 215篇 |
2010年 | 132篇 |
2009年 | 140篇 |
2008年 | 174篇 |
2007年 | 155篇 |
2006年 | 130篇 |
2005年 | 143篇 |
2004年 | 127篇 |
2003年 | 116篇 |
2002年 | 93篇 |
2001年 | 74篇 |
2000年 | 53篇 |
1999年 | 53篇 |
1998年 | 36篇 |
1997年 | 21篇 |
1996年 | 19篇 |
1995年 | 29篇 |
1994年 | 31篇 |
1993年 | 17篇 |
1992年 | 29篇 |
1991年 | 37篇 |
1990年 | 34篇 |
1989年 | 34篇 |
1988年 | 22篇 |
1987年 | 25篇 |
1986年 | 35篇 |
1985年 | 21篇 |
1984年 | 44篇 |
1983年 | 43篇 |
1982年 | 24篇 |
1981年 | 22篇 |
1980年 | 19篇 |
1978年 | 24篇 |
1977年 | 17篇 |
1975年 | 18篇 |
1974年 | 17篇 |
1973年 | 17篇 |
1971年 | 17篇 |
1970年 | 15篇 |
排序方式: 共有3488条查询结果,搜索用时 15 毫秒
1.
2.
Holly A. Ingraham Mehran Goulian 《Biochemical and biophysical research communications》1982,109(3):746-752
Deoxyuridine triphosphatase has been purified from cultured human lymphoid cells in high yield and stable form by a relatively simple procedure. The properties differed somewhat from those reported previously, e.g. apparent Km, molecular weight, and effects of divalent metals. No other naturally occurring dNTP or NTP serves as substrate, however, the enzyme may be an important site of interaction with intracellular derivatives of analogues of dUrd. It is shown here that deoxyuridine triphosphatase acts on araUTP, 6-azadUTP, 2′-FdUTP, and 2′,3′-dideoxyUTP, but the enzyme has no effect on 5-C1dUTP, 5-BrdUTP, 5-HgdUTP and dUrd-5′[α-thio]triphosphate. For the preparation of one of the analogues, the enzyme, trans-N-deoxyribosylase, from Lactobacillus, was used to prepare the deoxynucleoside from the base, a procedure that may have general usefulness. 相似文献
3.
4.
Vincent Anquetil Caroline Le Sommer Agn��s M��reau Sandra Hamon Hubert Lerivray Serge Hardy 《The Journal of biological chemistry》2009,284(47):32370-32383
Alternative splicing of 3′-terminal exons plays a critical role in gene expression by producing mRNA with distinct 3′-untranslated regions that regulate their fate and their expression. The Xenopus α-tropomyosin pre-mRNA possesses a composite internal/3′-terminal exon (exon 9A9′) that is differentially processed depending on the embryonic tissue. Exon 9A9′ is repressed in non-muscle tissue by the polypyrimidine tract binding protein, whereas it is selected as a 3′-terminal or internal exon in myotomal cells and adult striated muscles, respectively. We report here the identification of an intronic regulatory element, designated the upstream terminal exon enhancer (UTE), that is required for the specific usage of exon 9A9′ as a 3′-terminal exon in the myotome. We demonstrate that polypyrimidine tract binding protein prevents the activity of UTE in non-muscle cells, whereas a subclass of serine/arginine rich (SR) proteins promotes the selection of exon 9A9′ in a UTE-dependent way. Morpholino-targeted blocking of UTE in the embryo strongly reduced the inclusion of exon 9A9′ as a 3′-terminal exon in the endogenous mRNA, demonstrating the function of UTE under physiological circumstances. This strategy allowed us to reveal a splicing pathway that generates a mRNA with no in frame stop codon and whose steady-state level is translation-dependent. This result suggests that a non-stop decay mechanism participates in the strict control of the 3′-end processing of the α-tropomyosin pre-mRNA. 相似文献
5.
6.
7.
8.
Jonathan T. Sims Sourik S. Ganguly Holly Bennett J. Woodrow Friend Jessica Tepe Rina Plattner 《PloS one》2013,8(1)
Despite advances in cancer detection and prevention, a diagnosis of metastatic disease remains a death sentence due to the fact that many cancers are either resistant to chemotherapy (conventional or targeted) or develop resistance during treatment, and residual chemoresistant cells are highly metastatic. Metastatic cancer cells resist the effects of chemotherapeutic agents by upregulating drug transporters, which efflux the drugs, and by activating proliferation and survival signaling pathways. Previously, we found that c-Abl and Arg non-receptor tyrosine kinases are activated in breast cancer, melanoma, and glioblastoma cells, and promote cancer progression. In this report, we demonstrate that the c-Abl/Arg inhibitor, imatinib (imatinib mesylate, STI571, Gleevec), reverses intrinsic and acquired resistance to the anthracycline, doxorubicin, by inducing G2/M arrest and promoting apoptosis in cancer cells expressing highly active c-Abl and Arg. Significantly, imatinib prevents intrinsic resistance by promoting doxorubicin-mediated NF-κB/p65 nuclear localization and repression of NF-κB targets in a STAT3-dependent manner, and by preventing activation of a novel STAT3/HSP27/p38/Akt survival pathway. In contrast, imatinib prevents acquired resistance by inhibiting upregulation of the ABC drug transporter, ABCB1, directly inhibiting ABCB1 function, and abrogating survival signaling. Thus, imatinib inhibits multiple novel chemoresistance pathways, which indicates that it may be effective in reversing intrinsic and acquired resistance in cancers containing highly active c-Abl and Arg, a critical step in effectively treating metastatic disease. Furthermore, since imatinib converts a master survival regulator, NF-κB, from a pro-survival into a pro-apoptotic factor, our data suggest that NF-κB inhibitors may be ineffective in sensitizing tumors containing activated c-Abl/Arg to anthracyclines, and instead might antagonize anthracycline-induced apoptosis. 相似文献
9.
10.
Cervicofacial rhytidectomy 总被引:1,自引:0,他引:1